Back to Results
First PageMeta Content
Oral surgery / Glycosaminoglycans / Clinical research / Pharmaceutical industry / Restylane / Lip enhancement / Hyaluronan / Clinical trial / Adverse event / Medicine / Surgery / Oral and maxillofacial surgery


Microsoft Word - Executive Summary Add.FINAL-Mail.doc
Add to Reading List

Open Document

File Size: 137,54 KB

Share Result on Facebook

City

Pivotal / Study / Scottsdale / /

Company

Addendum Executive Summary Medicis Aesthetics Inc. / Medicis Aesthetics Inc / Applicant/Manufacturer Information Medicis Aesthetics Inc. / Clinical Studies Medicis Aesthetics Inc. / ITT / /

Country

United States / /

Currency

pence / /

Event

FDA Phase / /

IndustryTerm

lip augmentation / /

MedicalCondition

Insomnia / Herpes Infections / Injury / Poisoning / Infections / Gastrointestinal Disorders / General Disorder / Nutrition Disorders / /

MedicalTreatment

retreatment / Restylane / Plastic and Reconstructive Surgery / /

Organization

Single Center / Food and Drug Administration / Center for Devices and Radiological Health / FDA / Division of Surgical / Orthopedic / and Restorative Devices / /

Person

Treating Investigator / Fitzpatrick Types IV / V / /

Position

Investigator / general U.S. population / initial Executive / Executive / randomized / comparative evaluator / General / Blinded Evaluator / /

Product

Restylane injections / Restylane injection / Perlane injections / Perlane injection / MA-1400-01 / P040024 / MA-04003 / /

ProvinceOrState

Arizona / /

PublishedMedium

the FDA review / /

Technology

research protocols / /

SocialTag